1-苄基-3-氰基吡咯烷 | 10603-52-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苄基-3-氰基吡咯烷
• 中文别名: 1-苄基吡咯烷-3-羧酸酰肼；1-苄基吡咯烷-3-甲腈；1 -苄基吡咯烷- 3 -羧酸酰肼
• 英文名称: 1-benzyl-pyrrolidine-3-carbonitrile
• 英文别名: 1-Benzylpyrrolidine-3-carbonitrile
• CAS: 10603-52-8
• 化学式: C₁₂H₁₄N₂
• mdl: MFCD05662780
• 分子量: 186.257
• InChiKey: RYCQUUNQHVAFSM-UHFFFAOYSA-N

物化性质

• 沸点：
  120 °C(Press: 0.4 Torr)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36
• 海关编码：
  2933990090
• WGK Germany：
  3
• 危险标志：
  GHS06
• 危险性描述：
  H301,H319
• 危险性防范说明：
  P301 + P310,P305 + P351 + P338
• 包装等级：
  III
• 危险类别：
  6.1
• 危险品运输编号：
  3439
• 储存条件：
  室温条件下。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Benzylpyrrolidine-3-carbonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Benzylpyrrolidine-3-carbonitrile
CAS number: 10603-52-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H14N2
Molecular weight: 186.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

1-苄基吡咯烷-3-羧酸酰肼是一种用于医药合成的中间体，属于酰肼类有机物。

反应信息

• 作为反应物：
  描述：

  1-苄基-3-氰基吡咯烷 在 锂硼氢 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 6.5h， 生成 4-(3-(aminomethyl)-1-benzylpyrrolidin-3-yl)butan-1-ol
  参考文献：
  名称：

  [EN] COMPOUNDS
  [FR] COMPOSÉS

  摘要：

  本发明涉及大环化合物，例如大环磺酰基三唑。本发明还涉及相关的盐、溶剂化合物、前药和药物组合物，以及利用这些化合物在治疗和预防医学疾病和疾病中的应用，尤其是通过NLRP3抑制。

  公开号：

  WO2021165245A1
• 作为产物：
  描述：

  1-苄基-3-氨基吡咯烷 在 diethylzinc 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 nickel dichloride 、 zinc dibromide 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 16.5h， 生成 1-苄基-3-氰基吡咯烷
  参考文献：
  名称：

  镍催化的脱氨基氰化：腈和烷基胺的一碳同系化

  摘要：

  已开发出一种镍催化的 Katritzky 吡啶鎓盐的脱氨基氰化反应。当它与由伯胺形成吡啶鎓盐结合时，该方法能够将烷基胺转化为烷基腈。使用毒性较小的氰化物试剂 Zn(CN) 2，并且可以耐受多种官能团和杂环。除了多功能腈基的许多其他潜在转化之外，该方法还可以通过还原腈产物实现烷基胺的单碳同系化。

  DOI：

  10.1021/acs.orglett.1c01959

文献信息

• [EN] 1-(4-PIPERIDINYL) BENZIMIDAZOLONES AS HISTAMINE H3 ANTAGONISTS<br/>[FR] 1-(4-PIPERIDINYL) BENZIMIDAZOLONES UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR H3 DE L'HISTAMINE
  申请人：SCHERING CORP

  公开号：WO2003103669A1

  公开（公告）日：2003-12-18

  Disclosed are histamine H3 antagonists of the formula (I) wherein R1 is benzimidazolone derivative, M1 and M2 are optionally substituted carbon or nitrogen, R2 includes optionally substituted aryl or heteroaryl, and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula (I). Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula (I) in combination with a H1 receptor antagonist.

  揭示了公式（I）中的组胺H3拮抗剂，其中R1是苯并咪唑酮衍生物，M1和M2是可选择地取代的碳或氮，R2包括可选择地取代的芳基或杂环基，其余变量如规范中所定义。还揭示了包括公式（I）化合物的药物组合物。还揭示了使用公式（I）化合物治疗各种疾病或症状的方法，例如过敏、过敏引起的气道反应和充血（例如，鼻塞）的方法。还揭示了使用公式（I）化合物与H1受体拮抗剂结合治疗各种疾病或症状的方法，例如过敏、过敏引起的气道反应和充血（例如，鼻塞）。
• [EN] BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS<br/>[FR] BIS-PYRIDYLPYRIDONES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'HORMONE DE MÉLANO-CONCENTRATION
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010141538A1

  公开（公告）日：2010-12-09

  The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1 ), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.

  这项发明提供了新型的双吡啶基吡啉酮，它们是黑素浓集激素受体1（MCHR1）的拮抗剂，包含它们的药物组合物，它们的制备方法，以及它们在治疗和治疗肥胖和糖尿病中的用途。
• Antibacterial compounds
  申请人：Anderson D. David

  公开号：US20050159423A1

  公开（公告）日：2005-07-21

  Bacterial protein synthesis-inhibiting compounds having formula (I) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates in the processes, compositions containing the compounds, and methods of using the compounds are disclosed.

  抑制细菌蛋白质合成的化合物具有式(I)及其盐、前药、前药的盐，制备该化合物的方法和制备过程中的中间体，含有该化合物的组合物，以及使用该化合物的方法被披露。
• 一种烷基腈类化合物的制备方法
  申请人：中国科学院上海有机化学研究所

  公开号：CN111099941B

  公开（公告）日：2022-10-18

  本发明公开了一种烷基腈类化合物的制备方法。本发明提供了一种如式I所示的烷基腈类化合物的制备方法，其包括如下步骤：在溶剂中，在添加剂和催化剂的存在下，将Zn(CN)2与如式II所示的烷基卤化物进行如下所述的偶联反应，得到式I所示的烷基腈类化合物即可；所述的添加剂包括碱；所述的催化剂包括镍类化合物和膦配体；所述的镍类化合物为0价镍、一价镍盐和二价镍盐中的一种或多种；当所述的镍类化合物包含0价镍或二价镍盐时，所述的催化剂还包括还原剂。本发明的制备方法可以以廉价的催化体系，简捷高效地实现烷基卤化物的氰基化，而且还具有良好的官能团兼容性和底物普适性。
• Indole, azaindole and related heterocyclic pyrrolidine derivatives
  申请人：——

  公开号：US20030236277A1

  公开（公告）日：2003-12-25

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with amido piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

  这项发明提供了具有药物和生物影响特性的化合物，它们的药物组合物和使用方法。具体来说，该发明涉及酰胺哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染剂、免疫调节剂或HIV进入抑制剂结合使用。更具体地，本发明涉及HIV和艾滋病的治疗。